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This paper  focuses  on  the  processes  and  strategies  of  advocates  and  opponents  in  creating,  maintaining
and/or  contesting  the  protective  spaces  in which  ‘urgently  needed’  but  ‘risky’  pharmaceutical  innovations
are  managed.  Drawing  on  transition  literature  and  recent  work  on  niche  protection,  this  paper  adds  to  the
conceptualisation  and  empirical  grounding  of  niche  protection  by studying  the dynamics  of protection,
in  particular  the  different  phases  of  niche  development.  Moreover,  the  links  between  niche  protectioneywords:
rotective space
iche
arratives
ast access to innovations
harmaceutical sector
processes  and protection  strategies  pursued  by  niche  players  are  explored.  Dynamics  of niche  protection
are  explored  in  two  case  studies:  the monitoring  of  treatments  for  HIV  and  of  a vaccination  against  pan-
demic  inﬂuenza.  We  conclude  that  niche  protection  depends  on interactions  between  network  building,
empowerment  activities  and  the  construction  of  a  positive  niche  narrative  vis-à-vis  anti-narratives  raised
by  actors  outside  the  niche.  Furthermore,  the  nature  of  learning  within  a niche  and  the  niche’s  robustness
are  determined  by whether  the  strategies  are  predominantly  accommodating  or restrictive.
 2014©
. Introduction
New pharmaceutical technologies often have a bicephalous
haracter in that they tend to simultaneously produce both positive
nd negative effects. This dichotomy becomes especially delicate
hen the technology is perceived by a signiﬁcant group of actors
s being urgently needed, while its being introduced too quickly
ould endanger the thorough investigation of its negative impacts.
his balancing act between providing early access and ensuring
ufﬁcient evidence regarding impacts is relevant for pharmaceuti-
al innovations that aim to meet so-called ‘unmet medical needs’
EMA, 2010). When clinical trials show that a new pharmaceutical
roduct has a promising safety and efﬁcacy proﬁle, patients and
edical professionals often demand early access to this drug. In a
ense, they act as ‘lead users’, being the ﬁrst to face the need for
n innovation and to have strong incentives to use it (Von Hippel,
986).
One way out of this delicate balancing act is to introduce the
nnovative drug in a demarcated space. Such a space calls for
ailor-made measures to be taken, e.g. setting up speciﬁc safety
onitoring systems tuned to the disease or type of therapy.
herefore, the space is differentiated not only technically, but even
∗ Corresponding author. Tel.: +31 0302532708.
E-mail address: w.p.c.boon@uu.nl (W.P.C. Boon).
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ttp://dx.doi.org/10.1016/j.respol.2014.01.005
Open access under CC BY-NC-ND The  Authors.  Published  by  Elsevier  B.V. 
more so in socio-institutional terms. The demarcated, speciﬁc
character of the space often deviates from the regular safety
monitoring of drugs and therefore sometimes needs protection.
This article delves into the challenges of managing the protection
of monitoring practices for pharmaceutical innovations that are
perceived by a signiﬁcant group of actors as urgently needed.
The introduction of novel pharmaceutical products is heavily
regulated. Regular safety surveillance of drugs is regulated by a
formal and standard set of procedures and rules. Before market
introduction three phases of clinical trials need to show that the
drug is sufﬁciently safe, efﬁcacious and of good quality. After mar-
ket introduction, monitoring continues through a standardised
and automated way of collecting, validating and evaluating safety
reports (cf. Fraunhofer, 2006 for a detailed overview), together
forming a standard drug regulation regime.
The socio-institutional embedding of pharmaceutical products
dealing with unmet medical needs deviates from this regime. To
some extent, the term ‘urgently needed’ is subject to contesta-
tion, because actors can differ in the extent to which they demand
fast access to a drug. At the same time, US and EU governments
have instated speciﬁc pathways to regulate market introduction
of ‘urgently needed’ products, e.g. in the form of accelerated
approvals. In these regulations the term ‘unmet medical needs’ is
codiﬁed. The Food and Drug Administration in the USA  deﬁnes them
as ‘needs that are not addressed adequately by an existing therapy’
Open access under CC BY-NC-ND license.(FDA, 2006). The EU regulation explicitly points out speciﬁc dis-
ease areas to which these fast access regulations are applicable,
viz. HIV, cancer, pandemic inﬂuenza and rare diseases (European
Commission, 2006).
 license.
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The accelerated procedures enable fast market introduction by
lleviating pre-marketing testing requirements, such as passing
ver large-scale and expensive phase III clinical trials. In return,
ompanies must commit to stricter post-marketing safety monitor-
ng. This post-marketing surveillance, however, is less standardised
nd leaves room for ﬂexible, disease- and country-speciﬁc solu-
ions. These monitoring practices (and the related medical practice
f drug prescription and use) need to be protected from regular
rocesses, otherwise the legitimacy of fast introduction can come
nder pressure. Although these arrangements can be regarded as
xceptional, regulatory developments show that these protective
paces may  become more prevalent in the future. In 2011, the
uropean Medicines Agency (EMA) provided openings for a more
exible approach to drug approval in its Road Map  2015. One
onsequence could be that several approval procedures and post-
arketing surveillance practices will co-exist, protected from the
tandard EMA  drug approval procedure. Some scholars extend this
dea and foresee a ‘transformative’ overturn of regulations at the
egime level of drug development (Eichler et al., 2008). From a
echnology perspective, the advent of personalised medicine and
harmacogenomics might lead to more fragmented use of drugs,
nding in a growing number of small disease categories, increas-
ngly resembling the rare disease ﬁelds (Boon and Moors, 2008).
hese new developments indicate that more protective spaces of
ost-marketing monitoring are to be expected in the future.
Although US and EU regulations are in place to govern acceler-
ted approvals of drugs, the way in which post-market monitoring
hould be designed is not dictated. Lead users, such as patients
nd medical professionals, attempt to organise these practices
ailored to their particular (disease-speciﬁc) context. This article
tudies two disease areas, HIV and pandemic inﬂuenza, in which
atients and medical professionals perceived an urgent need for
ew medicines and organised their own tailor-made or idiosyn-
ratic monitoring practices.
To design and pursue these monitoring practices, there needs
o be room for experimentation and improvement before they are
trong enough to face the rigours of the rules dictating the domi-
ant regime. Niches are considered to be protective spaces in which
hese experiments can be pursued. The ‘niche’ concept is part of
he transition literature that conceptualises how new and emerg-
ng technologies are explored and developed against a backdrop of
xisting technologies and the associated socio-technical regimes
nd landscapes (Schot et al., 1994; Geels and Schot, 2007a).
This paper contributes to the existing literature on strategic
iche management in two ways. First, it builds on recent work
n niche protection by Smith and Raven (2012), in which they
erceive niche protection as under-conceptualised. They identify
hree processes of protection: shielding, nurturing and empow-
ring. The introduction of empowerment as a protective dynamic
s interesting, as it emphasises the importance for niche actors to
rticulate narratives and the related perceptions of urgency as well
s how they position their niche vis-à-vis actors who actively or
assively contest these narratives. In the context of pharmaceutical
nnovation, this reinforces that post-marketing monitoring is a way
o enable the quick development and diffusion of drugs that meet
nmet medical needs. This paper adds to the conceptualisation and
mpirical grounding of niche protection by studying the dynamics
f protection, i.e. by studying the interrelations between the three
rotection processes over different phases of niche development.
iche formation processes have been recently studied (Hermans
t al., 2013), but the focus on protection is new. Since stakeholders
roactively seek to organise or contest these niche processes,
he links with protection strategies are also investigated. Second,
his paper applies the concepts of niche protection to the ﬁeld
f drug development that is subjected to accelerated approval
rocedures. This provides us with the opportunity to augment thelicy 43 (2014) 792–803 793
emphasis on technical artefacts being protected in niches with
socio-institutional practices, such as post-marketing monitoring
practices. In line with this, the following research question is
answered: How do interactions between protection processes inﬂu-
ence niche development? And how do these processes inﬂuence niche
protection strategies?
This paper is set up as follows. Section 2 discusses the theoreti-
cal background of managing the protection of niches and explores
concepts that can aid the study of the dynamics of and strategies for
the development of these niches. Section 3 presents the method-
ology. Sections 4 and 5 provide the results for the HIV case and for
the pandemic inﬂuenza case. The paper ends with conclusions and
discussion (Sections 6).
2. Management of niche protection
2.1. Innovating in protective spaces
Transition literature has focused on path-breaking innovations,
mostly in the context of sustainability (Schot and Geels, 2008).
These innovations are developed in niches protected from the
selection pressures of the socio-technological regime comprising
the prevailing, dominant technological design (Hoogma et al., 2002;
Raven, 2006). Premature exposure to these pressures would prob-
ably mean elimination of the technological option in question (Rip,
1995; Schot et al., 1994). The characteristics of innovations, such
as technical and design speciﬁcations of and demands for novel-
ties, need to be gradually and interactively developed and become
more concrete over time (Schot et al., 1994). Early-stage, bottom-
up development in niches has been deemed successful when the
niche practices have broken out into the dominant regime, chang-
ing the rules of this regime to suit the novel technology along the
way (Geels and Schot, 2007a).
As part of this strand of literature, attention has been paid to the
processes inside these niches (Raven, 2005; Ulmanen et al., 2009)
and not so much to protection. Some classiﬁcations about niche
protection have been made, e.g. that protection should be tempo-
ral and phased out in time, to avoid too generous support and lazy
actors (Nill and Kemp, 2009). Protection and selection pressures
should be regarded as part of a careful balancing act; even in heavily
guarded niches selection pressures are never far away (Geels and
Schot, 2007b; Hommels et al., 2007). Even in these discussions,
however, protection has been perceived as a given fact and has
been under-conceptualised (Smith and Raven, 2012).
2.2. Protection processes in different phases of niche protection
Development of a speciﬁc new technology may  beneﬁt from
temporal shielding from selection pressures by creating protective
spaces or niches. Smith and Raven (2012) introduce three processes
that need to be facilitated to provide sufﬁcient niche protection:
shielding, nurturing and empowerment.
Shielding is an outward-oriented activity, focusing on moderat-
ing or fencing off pressures presented by the selection environment.
In this way it attempts to provide room for experimentation. Shiel-
ding can take an active form, i.e. when a protective space is created,
or a passive form, such as when the space coincides with a pre-
existing and low-proﬁle setting. Nurturing refers to processes that
support technology development within the niche. Earlier studies
on niche dynamics uncovered three processes as being signiﬁ-
cant to internal niche development: stimulating learning processes,
articulating expectations and building networks (Kemp et al., 1998;
Schot and Geels, 2008).
Whereas shielding and nurturing have already been part of the
transition literature vocabulary for a few years, the third process,
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Table 1
Characteristics of restrictive and accommodating strategic niche management.
Restrictive protection
strategy
Accommodating
protection strategy
Nurturing
Network building Concentrated and
homogeneous network; no
ﬁt between included and
excluded actors
Dispersed and
heterogeneous
network; ﬁt between
included and excluded
actors
Learning Fast ﬁrst-order learning;
little reﬂection as part of
second-order learning
Slower ﬁrst-order
learning; much
reﬂection as part of
second-order learning
Articulating
expectations
Robust expectations as
guidance
Expectations in ﬂux
Empowerment94 W.P.C. Boon et al. / Resea
mpowerment,  is new. Smith and Raven introduce empowerment,
ith which they mean efforts to increase the strength or compet-
tiveness of a niche, to underline that niche protection is also a
olitical activity by actors both within and outside the niche. For
xample, in the ﬁeld of sustainability, niches dedicated to speciﬁc
lternative energy sources are supported by public policy meas-
res. In order to sustain this support, niche actors need to maintain
 narrative to lobby their case. Actors outside the niche might con-
est these narratives or articulate anti-narratives. Using narratives,
iche advocates constantly negotiate relationships between the
ontent of the niche project and its wider context (Law and Callon,
994; Smith et al., 2013).
While studying the three niche protection processes, the ques-
ion arises as to what extent they differ during the development
hases of niches, these being creation, maintenance and phasing
ut. The creation of niches is associated with the articulation of
xpectations, promises and visions, leading to a shared agenda.
n the context of this paper, examples include regulatory agencies
xpecting a novel pharmaceutical product to be able to meet unmet
edical needs, and government agencies proclaiming the spread of
 disease as an emergency situation. These expectations can even
ecome ‘performative’ (Borup et al., 2006); they coordinate and
otivate actors to act upon the shared agenda (Van Lente, 1993).
n this way, stakeholders’ engagements, mutual dependencies and
 shared agenda might produce rhetoric and resources for the cre-
tion of niches (Schot and Geels, 2008). It is assumed that shielding
easures are the processes most often introduced at this stage, i.e.
n the form of agreements or resources made available.
In the maintenance phase, shielding can best be regarded as
n activity organised in the early formation stages of a niche and
ontinuing throughout its lifetime, e.g. governmental agencies pro-
iding resources to sustain a monitoring system. In this phase
hielding is eclipsed by nurturing activities, i.e. developing and
aturing the internal niche practices through learning and network
uilding. For example, medical specialists, scientists and patient
rganisations interact more frequently and exchange knowledge
bout side effects and best monitoring practices. With regard to
earning, we distinguish between learning about facts (ﬁrst-order)
nd about values and norms (second-order learning; Grin and Van
e Graaf, 1996). Empowerment activities also support niche main-
enance because during this phase the niche narrative is expanded,
.g. based on the expectations articulated and the activities per-
ormed. Communicating the niche narrative to external parties
ight simultaneously incite antagonistic voices, e.g. people who
nd it an exaggeration to call it a state of emergency.
Finally, the last stage of the existence of a niche pertains to
ts phasing out.  Niches vary in the degree to which their prac-
ices are institutionalised and the extent to which these practices
econﬁgure the regime. Niche practices can be developed in such
 way that they ‘ﬁt into and conform to’ the rules of the current
egime. Another venue is that niche innovations generate signiﬁ-
ant changes at the regime level, in such a way that the rules of the
election environment are ‘stretched and transformed’ (Smith and
aven, 2012). In this article, the idiosyncratic monitoring practices
an either be incorporated in standard drug surveillance or they can
hange the overall regime practices of drug regulation. Understand-
ng the relation between niches and the regime is crucial in studying
iche protection and as such is integral to our explorations.
.3. Strategies for niche protection
In the context of niche protection, several strategies can be
iscerned, including arbitration of differing views, creating a plat-
orm for discussion, negotiating compromises, capturing others’
erspectives and broadening the scope of the niche, or ignoring
ther voices. The dynamics of niche protection processes hasNo engagement with
anti-narratives
Capturing of ideas from
outsiders
repercussions for the ways actors deploy strategies to protect their
niche. For example, network building can be pursued in different
ways, leading either to homogeneous/concentrated or heteroge-
neous/dispersed networks, in turn producing either a restrictive or
an accommodating strategy. This degree of ‘openness’, meaning the
degree to which different views and interests are accommodated
by the lead actors, is central to niche protection in the context of
pharmaceutical innovations because these innovations are often
subject to contestation and are traditionally coordinated by the
closed medical community.
To show the inﬂuence of niche protection dynamics on strate-
gies, two  “extreme” poles are sketched in terms of openness:
accommodating and restrictive strategies. Integral to this dis-
tinction between accommodating and restrictive is the notion of
niche boundaries. By this, we  mean that niche boundaries are the
result of how actors within and outside niches position them-
selves and others, for example as expressed through narratives and
anti-narratives. Articulating these narratives through protection
processes, such as empowerment activities, leads to the opening up
or closing down of the niche boundaries. In this light, niche advo-
cates choose to follow either an accommodating or a restrictive
strategy when managing their niche and their relations with the
niche context. Table 1 shows this close relationship between the
niche protection processes and the two strategic poles.
The next section describes the methodology used to study vari-
ous approaches to strategic management of niche protection in the
context of monitoring urgent pharmaceutical innovations.
3. Methods
In order to study the management of implementing “urgent but
risky” pharmaceutical innovations, two cases were selected. These
cases were expected to differ from each other along the lines of
the two  strategies introduced in the previous section, in this way
forming typical representatives of restrictive and accommodating
protection strategies in the pharmaceutical sector. Following the
US, the European Union introduced regulations to ensure fast access
to novel products while at the same time calling for rigid targets on
post-marketing surveillance. These special regulatory pathways are
called conditional market authorisations, and approvals are issued
under exceptional circumstances. They are applicable to pharma-
ceutical products that meet “unmet medical needs” and are in the
interest of public health (European Commission, 2006). This regu-
lation focuses explicitly on three categories, namely: (a) seriously
debilitating or life-threatening diseases (e.g. cancer and HIV), (b)
medicines used in emergency situations (e.g. pandemic inﬂuenza),
and (c) drugs for rare diseases. From these categories two cases
rch Policy 43 (2014) 792–803 795
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Table 2
Operationalisation of concepts.
Dimensions Description of dimensions
Shielding (Smith and
Raven, 2012)
Active shielding Introduction of resources
(ﬁnancial support) or
legislation (rule
exemptions)
Passive shielding Framed as pre-existing and
low-proﬁle activity
Nurturing – network
building (Schot and
Geels, 2008)
Concentration and
interactions inside
niche
Level of concentration and
intensity of interactions
Level of
recruitment of
actors outside the
niche
Openness to network
participation; active
recruitment of excluded
actors
Degree of ﬁt
between included
and excluded
actors
Subjective evaluation of
actors of niche inclusion
Nurturing – learning
(Grin and Van de Graaf,
1996)
First-order learning Developing demands, ideas
and solutions
Second-order
learning
Developing underlying
values and norms
Nurturing –
articulating
expectations
(Van Lente, 1993)
Expectations Changes in expectations
and their concreteness
Empowerment (Smith
and Raven, 2012)
Development of a
niche narrative
Actors inside the niche
articulating importance of
the niche and its protection
Relation to
narratives of actors
Actors engaging in
conversation with actors
searched ﬁve leading newspapers and three weekly opinion mag-
azines that cover a wide range of social and political perspectives.2
The articles were read and events and quotations were selected. In
2W.P.C. Boon et al. / Resea
ere selected: HIV and pandemic inﬂuenza.1 Furthermore, these
ases were expected to potentially illustrate an accommodating
HIV) and a restrictive (inﬂuenza) protection strategy. By covering
he two “extremes” or “outliers” of the spectrum, the two  cases
resent rich information on the dynamics and strategies under
tudy (Eisenhardt, 1989).
The cases on HIV and pandemic inﬂuenza are studied in the
utch context of post-marketing surveillance and drug use. The
ocus of this paper is not so much on the phase before market
pproval and the formal rules for fast approval, but on the imple-
entation of the product innovation in combination with new and
ailor-made safety monitoring practices. We  focus on one coun-
ry, the Netherlands, because a large part of the socio-institutional
ractices of drug implementation and post-marketing surveillance
s country-speciﬁc. Furthermore, in the case of HIV many interna-
ional initiatives originated in the Netherlands. Nevertheless, the
harmaceutical sector is an international business and has increas-
ngly been regulated and monitored on an international level.
nternational developments that typically inﬂuence national moni-
oring institutions were included in the analysis. The moment when
ublic and private parties started to pay attention to pharmaceu-
ical interventions was chosen as a starting point for the in-depth
ase analysis of niche protection processes and strategies. For HIV
his means from the initial discovery of the disease in the early
980s onwards, and for pandemic inﬂuenza from 2009 to 2010.
he differences in duration of the cases was a possible signal of a
istinction in the level of contestation of the niche’s existence, as
he size and urgency of pandemic inﬂuenza was more contested in
 shorter period of time. However, it became clear that all cases on
rgently needed innovations concerned periods of high intensity
n terms of contestation.
The analysis draws on four different data sources. First, 40
n-depth interviews with representatives of all relevant parties
ere conducted. These relevant parties included regulatory agen-
ies, companies, patient organisations, payers, medical specialists,
urse practitioners, pharmacists, university researchers, and phar-
acovigilance centres. It should be emphasised that the interview
espondents were key informants within the two  cases. To ensure
eliability of data collection and analysis, all of the semi-structured
nterviews were audio-taped and fully transcribed for further anal-
sis. These were then coded, based on the dimensions mentioned
n Table 1, which are further operationalised in Table 2. The partici-
ants consented to these recordings on condition of anonymity and
estricted use for the purpose of this study. In the descriptions of the
wo case studies the respondents are made anonymous and coded
s R1, R2, etc. During the interviews the respondents were explic-
tly asked to reﬂect on the role and anonymous statements of other
ctors in order to validate these statements. Because the range of
otential interview respondents is conﬁned, e.g. the number of HIV
atient organisations is limited, we aimed to contact and interview
s complete as possible a set of stakeholders. In most cases, initial
ontact was made through e-mail, although sometimes an intro-
uction was made by a member of the multi-stakeholder workshop
see below) or other interview respondents.
Second, the interview data were substantiated and triangu-
ated by desk research. The source literature included: (1) data
n conditional approvals and approvals under exceptional cir-
umstances (safety issues, speed of market access, etc.), based
n studying the European Public Assessment Reports (EPARs)
f drugs being developed; (2) policy documents, scientiﬁc arti-
les, etc. which the interview respondents recommended; (3)
 literature search of the Scopus bibliographic database using
1 The rare diseases were excluded because they form a heterogeneous set of
ilments.outside niche outside niche and reacting
to  anti-narratives
(a combination of) keywords, including ‘conditional approval’,
‘approval under exceptional circumstances’, ‘early access’, ‘phar-
macovigilance’ and ‘post-marketing surveillance’. This was per-
formed in combination with keywords that restricted search results
to the disease areas under study and the related pharmaceutical
products.
Third, three multi-stakeholder workshops were organised,
involving a wide array of stakeholders in the ﬁeld of registration and
post-marketing surveillance in the Netherlands. The participants
included a doctor, an ethicist, industry representatives, represent-
atives from patient organisations, the Dutch ministry of health, the
pharmacovigilance centre, the Dutch Medicines Evaluation Board,
and public scientiﬁc research funders.
Fourth, a news analysis was conducted to collect data on impor-
tant events and statements by stakeholders. These data were
needed to check the extent to which the interpretations made by
interview respondents were supported by statements given by a
wider range of actors. The newspaper articles were extracted from
LexisNexis, a newspaper repository that provides access to prac-
tically all articles in Dutch newspapers from 1990 onwards. WeThe sources were: De Telegraaf; NRC Handelsblad; AD/Algemeen Dagblad;
Trouw; De Volkskrant; Reformatorisch Dagblad; Vrij Nederland; and Elsevier. Search
terms for the HIV case: (((hiv OR aids) AND (bijwerking OR medicijn OR  geneesmid-
del)) and Date(geq(01/01/1990) and leq(01/01/2000))). This yielded 361 articles.
For the period 1982–1989 we used quotes from the thorough historical overview of
HIV  in the Netherlands by De Mooij (2006) and our own interview results. Search
terms for the inﬂuenza case: (((mexicaanse griep OR pandemische griep) AND (vac-
cin OR bijwerking)) and Date(geq(01/04/2009) and leq(31/12/2010))). This yielded
170 articles.
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he case descriptions, quotations based on the newspaper analysis
re referred to with ‘NP’.
All events and statements pertaining to monitoring of new drugs
n HIV and pandemic inﬂuenza were extracted from the interviews,
esk research, workshop transcripts and newspaper articles. This
nformation was dated and included in an event history database
Van de Ven and Poole, 1990). The next step was to categorise the
vents into typologies based on the niche protection processes as
ntroduced in Section 2.2. To increase the (interrater) reliability of
his coding exercise, the processes were speciﬁed in the form of
imensions and elaborations of these dimensions, as exhibited in
able 2. These dimensions were used as coding categories. Finally,
he number of types of process events and statements was  graph-
cally laid out to show the prominence of each niche protection
rocess in different phases of niche development, indicating the
ynamics of protection processes in niches over time. The event
istory database also formed the backbone of the descriptions of
he two cases, since its time-ordered collection of events and state-
ents served as an historical account.
. HIV: close-knit community with a strong narrative
.1. Niche creation (1982–1986)
In 1982 AIDS arrived in the Netherlands. Since then the preva-
ence of the disease has grown rapidly, as has the attention paid
o it. Action was  needed because of its seriously debilitating, pro-
ressive and untreatable character. From the start, two types of
ctors attempted to dominate discussions: patients and medical
rofessionals. First, the majority of patients affected appeared to
e homosexuals, which caused unrest and panic in the relatively
losely knit community, largely concentrated in Amsterdam (R5;
7). Gradually, patients organised themselves, which led to a frag-
ented landscape of representative organisations, ranging from
IV-infected to seropositive, and from moderate (HIV Vereniging)
o more radical (Act Up!). Although representatives of the homo-
exual community wanted to control the disease’s spread, they
ere also concerned with avoiding social stigma. This position
ecame clear in 1983 when the blood banks, which were unable to
ecure the quality of their products, wanted to exclude homosex-
als from donating blood. Members of the gay community reacted
gainst this because ‘this would seriously damage the [emancipa-
ion] process in which they were engaged’ (De Mooij, 2004). This
iscussion positioned them against the haemophiliac patients who
eared for the quality of anticoagulants produced with HIV-infected
lood. ‘The interests of homosexuals dominated. Nobody wanted to
un the risk of being accused of discrimination’ (R31). Haemophil-
ac patients felt deserted by the government that ‘let it all happen’
R1).
Medical professionals in Amsterdam formed the second group of
nﬂuential actors. They worked in places to which patients turned
rst, such as at the municipal health service and the Amsterdam
niversity hospital. Many aspects of the disease were unknown
‘we were breaking new ground’, R6), still there was a need for
ublic communication and palliative treatment. Because of the
nknown and imminent threat, informal meetings and bilateral
ontacts led to unorthodox solutions, such as dedicated informa-
ion campaigns (1983), monitoring schemes of high-risk groups in
he Amsterdam Cohort Study (1984 onwards), and the opening of
 specialised ward at the university hospital with nurse practition-
rs or “HIV consultants” who specialised in supporting HIV patients
1986).
These two groups formed the advocates who attempted to
eﬁne an HIV niche in which idiosyncratic solutions for monitor-
ng safety could be initiated. These solutions were ﬁnanced throughlicy 43 (2014) 792–803
both dedicated and ad hoc public funding, which can be regarded
as active shielding. Governmental agencies were fast to provide
resources, not only due to the disease’s severity, but also because
they feared radicalisation of the patient community (De Mooij,
2004). There was  also room for passive shielding in the sense that
the prominent members of the homosexual community, who  were
regarded as well-educated and well-positioned (R2; workshop 1
and 2), were able to devote time and effort to organising idiosyn-
cratic solutions. The same applied to the medical professionals
involved: they were in the early stages of their careers and quickly
assumed the monopolistic role of HIV/AIDS expert. This role was
boosted by the concentration of HIV patients in Amsterdam and by
the fact that in Amsterdam medical specialists had already been
quite advanced in the haematology ﬁeld (R29; R30). All in all, the
creation of the HIV niche was characterised by a combination of
active and passive shielding, largely driven by articulated expec-
tations on fears for the unknown disease and for the possibility of
large-scale diffusion: ‘In the late 1980s and early 1990s patients
were in great despair: people died in large numbers. People were
frightened, and there was great pressure to do something about
the disease’ (R7). Empowerment played a part in the sense that the
gay community propagated homosexual emancipation as a leading
element in the communications and activities of the niche players.
During this stage the ﬁrst steps were taken to initiate a new scheme
to monitor HIV. Activities only really gained momentum after the
ﬁrst drug entered the market.
4.2. Niche maintenance (1987–1996)
Scientists at public institutes and pharmaceutical companies
diligently searched for treatment options. By following homosexu-
als (healthy, seropositive and HIV) and drug users, the Amsterdam
Cohort Study had produced a large and high-quality scientiﬁc
output. When the ﬁrst antiretroviral drug, AZT, entered the
Dutch market in 1987, two  scientists who  ran the cohort study
approached the AZT-producing ﬁrm and asked to use the limited
number of doses to set up a clinical trial. This collaboration formed
the starting point of a series of post-marketing clinical trials. As
short linkages existed between scientists, medical specialists and
company representatives, and as the industry was unsure how
to research and develop HIV drugs, there was  ample room for
investigator-initiated clinical trials. From 1990 onwards, these tri-
als were coordinated by the National AIDS Therapy Evaluation
Centre (NATEC), founded by the Amsterdam scientists and ﬁnanced
by the national government. The radical pressure group ACT UP!
was instrumental in securing funds for the centre: ‘When ACT
UP! sent an angry letter and threatened with actions, NATEC was
opened [. . .]  It is a disgrace [. . .]  AIDS is an emergency situation to
which one should react quickly’ (NP; also R6, R9).
Patients did not put innovation before safety at all costs. There
are ample examples of patient organisations questioning accel-
erated approvals for fear of suboptimal quality of science and
pharmaceutical products (Epstein, 1997). The introduction of the
antiretroviral drug AZT (1987), followed by ddI (1991) and ddC
(1992), instigated an increase in the attention paid to side effects.
AZT turned out to have severe side effects (R7), news of which
‘travelled fast’ through the close-knit network of patients, med-
ical professionals, scientists and pharmaceutical companies: ‘the
HIV world was  small and everyone knew each other’ (R6). Patients
and their representatives consistently depicted these drugs as ‘poi-
sonous’ or ‘AIDS on prescription’ (NP; R7; De Mooij, 2004) and
called for intensive monitoring of side effects. This led to the
organisation of rich, tightly connected arrangements of informal
initiatives and organisations for monitoring safety. These arrange-
ments grew organically from initiatives such as the Amsterdam
Cohort Study. Moreover, discussions on drug safety were largely
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nformal and took place in ‘a bottom-up way in the surgery or the
ard’ (R5). The basis of these discussions was formed by close con-
acts between doctors and patients: ‘Patients were very open. We
moked companionably during surgery visits [. . .]  We  experienced
 lot together’ (NP).
The bottom-up and organic nature of these initiatives meant
hat safety monitoring in the ﬁeld of HIV/AIDS was organised differ-
ntly from the regular drug monitoring system. The niche advocates
ad proper incentives to differentiate. Among others, the addi-
ional money for cohort studies presented opportunities for the
cientists involved to publish papers based on unique data, thus
aining recognition. This differentiation was eventually made per-
anent by an agreement between niche advocates, including the
edical specialists, patient representatives, and the Netherlands
harmacovigilance Centre Lareb (R11; R12; R16; workshop 2). This
greement ﬂagged the described underlying niche maintenance
rocesses: ﬁnancial support for NATEC (active shielding), demands
bout safety and quick access to drugs (articulating expectations),
nd the forming of tight connections between users, medical pro-
essionals and producers (network building).
The network of niche advocates, which by then consisted of
edical specialists and patient representatives, mostly situated
n the Amsterdam area, learnt about safety monitoring along the
ay. Patient representatives talked like doctors and scientists, e.g.
bout data requirements in the context of clinical trials and about
rug characteristics such as how they work and how adverse side
ffects should be perceived. A patient representative discussing an
nternational cohort study claimed that ‘the []-study has a few lim-
tations, such as the diversity of patients included. There is a need
or validation through an RCT or a second cohort study’ (R9). Episte-
ologically, patients aligned with medical professionals on how to
ollect and analyse data, and how to take action based on these data.
atients had a high level of access and control over post-marketing
urveillance through the personal contacts they maintained with
he initiators of these post-marketing efforts, e.g. through active
nvolvement in reporting adverse drug reactions (De Langen et al.,
008) and discussions on when to start AZT treatment (NP). Patients
lso had an incentive since they thought that ‘others, even includ-
ng doctors, were not interested in discerning the cause of their
hysical deterioration: whether it was the use of medicines or the
isease itself’ (NP).
This combination of network building, the articulation of expec-
ations and (second-order) learning fuelled the narrative that
einforced the niche boundaries and positioned the outside actors.
he latter took form in three types of confrontations. The ﬁrst
as “consumer clubs”: patients urgently needed new medicines
nd wanted to take risks. They did this by demanding access to
edicines that were still being tested in clinical trials (NP) or by
pening illegal routes to obtain medicines. These illegal routes
ecame heavily contested within the medical and patient com-
unities: they were not against illegal or risky use as such, but
hey wanted the effects to be monitored (NP). They wanted to be
nvolved, fearing that these “consumer clubs” would ‘go under-
round’ (NP).
Second, there were confrontations with alternative or tradi-
ional medicine practices that reacted against the ‘mathematical
ays’ of Western medicine (NP), thus attracting a lot of atten-
ion. The medical and patient communities dissociated themselves
rom these practices. The medical professionals were most articu-
ated about it, calling the promotion of these alternative views as
folklore’, ‘hot air’ or even ‘criminal’ (NP).
Third, the patient movement was dominated by homosexuals.
ear of stigmatisation of homosexuals because of AIDS led them to
roactively dominate certain areas of AIDS policy, such as com-
unication about prevention (De Mooij, 2004). This dominance
esulted in other patient groups being less well heard. Exampleslicy 43 (2014) 792–803 797
include drug abusers (who were regarded as “little brothers”),
immigrants from low-income countries, and seropositive people
who had slightly different interests in disease communication and
prevention (NP; R1). In this period the confrontation between the
niche advocates and the haemophiliac patient group ﬂared up again
over the latter’s wish to receive compensation from the govern-
ment for its not being conscientious enough with the quality of
donor blood, as this portrayed haemophiliac patients as ‘innocent
victims’ compared to other patients (NP).
The emphasising of the niche narrative reached its summit dur-
ing the introduction of protease inhibitors as a promising new drug
class in 1996, which marks one of the most striking and discussed
episodes in the Dutch HIV history. After admittance in the US, the
drug awaited European approval. This limited the market access of
the drug to a great extent: although off-label use is allowed under
certain conditions in the Netherlands, reimbursement for the drugs
formed a problem. The AIDS charity fund Aids Fonds and promi-
nent medical specialists zealously advocated for reimbursement
for the drug: ‘HIV patients don’t have the time to wait for bureau-
cratic decisions’ and ‘there is a medical need’ (NP). They had several
meetings with civil servants from the ministry of health. During one
of them the minister of health attended. She was  a physician by
training and had personally studied the scientiﬁc papers before the
meeting. Based on that information, she decided to act against the
recommendations of her civil servants and created a special reim-
bursement scheme (R6; R13; NP). ‘The civil servants were really
sputtering but then she suddenly said: “but you don’t have AIDS,
[name of civil servant]”’ (R6). In return, the minister insisted on
a closer surveillance of HIV drugs use. An observational cohort
project (the Athena project, later the Stichting HIV Monitoring) was
created, in which all patients were included and monitored.
4.3. Niche phasing out (1996–now)
The introduction of the new class of drugs, protease inhibitors,
created the possibility to prescribe combinational therapy that
appeared effective in suppressing – but not curing – the HIV virus.
AIDS became a manageable disease, which posed new challenges
such as therapy compliance, especially in the face of ‘patient-
unfriendly’ therapy regimes that ‘are hell’ and ‘ruin your social life’
(NP). Also, as people with the disease lived longer, this exposed
new side effects such as cardiovascular problems and abnormal
fat accumulation (lipodystrophy), leading to a ‘renewed ﬂooding of
hospitals’ (NP) and new monitoring initiatives such as the European
Data Collection on Adverse Events of Anti-HIV Drugs (R12).
These new developments ﬁt into the existing niche practices.
Discussions about adverse drug reactions and drug usage largely
remained within the surgery, in interactions between medical spe-
cialists, nurse practitioners and patients (R5; R9). News about side
effects circulated quickly: nurses had an e-mail service and medical
specialists called each other. Only occasionally did doctors report
side effects through regular channels (R7; R10). In other words, the
special arrangements had become more formalised but remained
different from the regular safety monitoring practice (R10; R16).
Network building and learning followed a similar pattern, becom-
ing larger-scale and more structured.
Pressure from actors outside the niche gradually subsided,
mostly because actors became part of the niche and adopted the
narratives of the niche. This was  the case with politicians and poli-
cymakers. Other actors, such as medical specialists in cities outside
Amsterdam, became involved because the geographical reach of
the niche widened. Partially, this happened because of the sheer
presence of HIV patients outside Amsterdam, and partially because
these medical specialists were included for strategic reasons. Other
patient categories that were originally excluded from the niche
were not potent or persistent enough to resist or inﬂuence the niche
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oundary. Strategies for empowerment were not very forceful.
he establishment’s fear that patients would radicalise was  always
lose to the surface, and this was seen as a powerful weapon for
he patient community (R4). However, they were quickly taken up
y the consultative (“polder”) structure of Dutch policymaking, and
ggressive activism made no headway (De Mooij, 2004). There was
lso no need for forceful empowerment, because the abovemen-
ioned anti-narratives were either articulated by far less powerful
ctors, or by actors whose narrative could easily be included in the
iche’s main narrative. The latter then led to capturing these actors
n the network of the niche.
At the same time, the separate status of the niche, and thus also
iche narrative, became the subject of discussions. The special sta-
us of HIV/AIDS was criticised in Dutch newspapers as early as 1992:
The amount of money reserved for AIDS, if one looks at severity
nd incidence, is not in proportion to cancer and rheumatism’; ‘The
edical profession is vexed with the amount of attention paid to
IDS’ (NP). In the same vein, some commentators disapproved of
he 1996 reimbursement debate: the decisions were made ‘miracu-
ously quickly’ and ‘lobbying was uncritically received’ (NP). Several
takeholders even began to question the degree to which the med-
cal need of HIV patients was still unmet (R5; R10; R14).
Especially after the introduction of two drugs in new antiretrovi-
al classes in 2007 and 2008, risk aversion regarding HIV medicines
eemed to grow. The need for novel drugs has been decreasing.
ecently approved medicines are only used if other drugs fail
nd if they show an apparent increase in user-friendliness (R5;
10). Medical specialists and nurse practitioners claim that more
ttention should be paid to the safety of new drugs: ‘Careful con-
ideration should be given to whether the accelerated approval of
 novel drug is ethically justiﬁed’ (R5).
Despite questions about the need for protection, there has not
een any serious political or policy discussion about this topic.
oliticians and policymakers have been part of the HIV niche net-
ork for years. ‘Regulators have not become more restrictive. This
ight be related to the credibility that has been built up over the
ears’ (R12) by companies, regulators and patient organisations.
herefore, it seems that the narrative of niche protection is slightly
hanging without affecting shielding or nurturing processes.
.4. In sum
The HIV case shows that a community of niche advocates,
onsisting of medical professionals and patients, dominated the
alancing between quick access to drugs and the establishment of
n elaborate set of safety monitoring initiatives. Through protection
easures, this set of initiatives was different from regular monitor-
ng. Fig. 1 depicts the dynamics of protection processes based on
he coding of events, i.e. the prominence of each niche protection
rocess in the various phases of niche development.
. Pandemic inﬂuenza: outside pressure on niche narrative
.1. Niche creation (April–May 2009)
In April 2009 the ﬁrst cases of what would later be known as the
exican ﬂu, or inﬂuenza A virus subtype H1N1, were discovered
n Mexico. The virus rapidly spread, and in June 2009 the World
ealth Organisation (WHO) declared the inﬂuenza as pandemic.
or years virology experts had warned health authorities that the
ver-changing genetic make-up of viruses would imply a statisti-
ally certain future inﬂuenza outbreak resembling the severity of
he 1918 Spanish ﬂu. Experts and authorities had already started
lanning for a possible new pandemic after the avian inﬂuenza out-
reaks in Asia at the end of the 1990s (EU, 2001; Fedson, 2004;licy 43 (2014) 792–803
Stephenson et al., 2004; WHO, 2003). One example of the prepara-
tions is the guideline produced by the European Medicines Agency
(EMA) in 2004, which described the way  in which inﬂuenza vac-
cines could be approved in an accelerated fashion (EMEA, 2004).
Pharmaceutical companies started to work on the development
of vaccines, the ﬁrst of which were approved in 2008. In the
Netherlands a set of strategies was  developed to deal with a viral
outbreak. Part of these plans included the foundation of the Out-
break Management Team, alongside several departmental steering
committees.
With the arrival of the Mexican ﬂu in the Netherlands at the end
of April, the Outbreak Management Team convened for the ﬁrst
time. In the media a prominent virologist warned for a large number
of casualties: ‘50 million people died from the Spanish ﬂu, which
started in the same way’ (NP; R22). During this early May  2009
period the messages about the seriousness of the inﬂuenza were
ambiguous. US ﬁgures show that the inﬂuenza was rather mild, and
commentators mockingly talked about it as a ‘CNN-outbreak’ (NP).
At the same time, the Dutch Health Council, consisting of medical
scientists and practitioners, underlined the risks and recommended
vaccination for certain high-risk groups (The Health Council of the
Netherlands, 2009). The minister of health followed this advice,
acquired 35 million vaccines and began to plan the vaccination. The
Health Council also explicitly articulated the need for a system to
monitor side effects.
The organisations and people involved with managing the vac-
cination operation had two  anxieties. First, they wanted to avoid
a repeat of the low vaccination coverage seen a year earlier with
the human papillomavirus (HPV) vaccination of female adolescents
in the Netherlands. ‘The HPV campaign was  seen as a predecessor
of the ﬂu campaign’ (R21). This vaccination campaign started dis-
cussions about the necessity and risks of these vaccines. Critical,
Internet-based groups were founded that produced countervailing
information against what they saw as ‘imperative’ demands made
by the Dutch government to take the vaccination (R20). Second, due
to the accelerated character of approving the vaccines and previous
experiences with inﬂuenza emergencies, safety issues could not be
ruled out altogether. Especially the increased incidence of Guillain-
Barré syndrome following inﬂuenza immunisation during the 1977
swine ﬂu pandemic was  cited (NP) as a reason to take adverse reac-
tions to inﬂuenza vaccinations seriously. Both anxieties led health
experts to underline ‘the importance of safety monitoring’ (NP).
The National Institute for Public Health and the Environment
(RIVM) had always been responsible for managing the vaccina-
tion programmes and had an elaborate monitoring system in
place for non-emergency vaccinations. However, both in infor-
mal  departmental deliberations and in the media, the interlinked
responsibilities were questioned at that time: ‘RIVM always steam-
rolls all objections; trust in vaccination is not helped by one
institution being responsible for planning, execution and evalua-
tion’ (NP). The RIVM agreed but responded that ‘we should not try
to come up with new pathways in times of emergency’ (NP).
The ministry responded to these pressures by delegating this
task to the Netherlands Pharmacovigilance Centre Lareb. Lareb
originated from a local initiative but had gradually grown into
a national platform. It perceived itself as ‘bottom-up, scien-
tiﬁcally engaged, no-nonsense and independent’ (R11). Others
acknowledged this independent character (NP). For years, Lareb
had been responsible for monitoring drug safety, but its remit
did not include vaccinations. The organisation took the inﬂuenza
pandemic as an opportunity to enter this subﬁeld of safety
monitoring, in the meantime introducing some novelties in post-
marketing surveillance. Lareb proactively made a scenario of how
to perform post-marketing surveillance in the case of a pan-
demic, but there were still issues that needed to be sorted out
(R18).
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In sum, the implementation of pandemic inﬂuenza vaccination
n 2009 was the ﬁrst time the Netherlands needed to respond
o an epidemic on a large scale and in a short period. Although
here had been preconceived ideas and scenarios as to how to deal
ith a pandemic, and RIVM had had an outbreak management
esponse structure in place (R23), the governance of immunisation
eeded to be worked out. The regular circuit of inﬂuenza experts
nd organisations specialised in vaccination could be regarded as
lose-knit. ‘The vaccination world is quite closed, with small groups
f experts who all know each other very well’ (R11). The sense
f urgency drove these experts into each other’s arms in prac-
ical form, through a ministry-coordinated “task force”. Still, the
onstellation was tentative and fragile because of the immature
nd contested nature of its organisation. These practices can be
egarded as being set up in a protective space. The ministry played
 central role and coordinated the niche in a top-down way, among
thers by providing resources to shield the niche from outside pres-
ure. Moreover, prominent scientists and civil servants canvassed
he severity of the pandemic, by forcefully articulating expectations
bout the need for safe vaccination.
.2. Niche maintenance (June–December 2009)
During the summer it became clear that the pandemic was
ilder than expected and ‘not any different from a seasonal ﬂu’
R25). This posed the ministry with the issue of whether to continue
reparing for vaccination. The voices of the niche advocates also
ecame mufﬂed, even to such an extent that they came personally
nder pressure as ‘scare mongers and doomsayers’ (NP). More-
ver, the press suspected one of the prominent niche advocates
f proﬁting from his ‘inﬂuenza prophecies’ through the shares
e owned in several companies. The contestation of expectations
ed to questions about the need for and safety of vaccination.
n editorial in The Lancet again drew parallels with the 1977
andemic in the US and warned against ‘accelerated safety trialsocesses over three phases of the HIV niche development.
under time pressure’ (NP). Dutch experts underlined this in the
media: ‘You give something to people who are not ill and certainly
don’t want to become ill’, but recognised that ‘absolute safety is a
utopia’ (NP). They also warned for ‘indifference [. . .]  we’re faced
with the difﬁcult situation that the general public is fed up with
the inﬂuenza even before it has really hit the Netherlands’ (NP).
Meanwhile, Lareb actively took up its new task and engaged
in ‘intensive contacts’ with RIVM, the ministry of health and the
two pharmaceutical companies (R23; R24; R25), as agreed upon
through mutual consent (R25). The government was  convinced that
adverse drug reactions were best monitored using a spontaneous
reporting system (Van Puijenbroek et al., 2010), complemented
by additional large-scale studies as requested by EMA  as part of
the accelerated approval procedure. Issues they needed to deal
with were the speed of monitoring, ‘given the large number of
people who had to be vaccinated in a short period of time’ (Van
Puijenbroek et al., 2010) and ‘noise’ in the reporting (NP). This
resulted in the implementation of an “intensive monitoring” sys-
tem on which Lareb had worked since 2006 but which would
then be applied in a real-life situation, which practically meant
that they needed to “learn on the job”. The system consisted of
web-based questionnaires that focussed on speciﬁc, spontaneously
reported side effects. The resulting reports ‘were checked on a daily
basis for seriousness’ (R18), allowing the opportunity to approach
the reporter or medical professional for additional questions. By
actively linking reports with the vaccine serial numbers, batches
could be withdrawn if needed. All parties involved in the vaccina-
tion process, including the companies, stimulated the vaccinated
people to report eventual side effects through Lareb.
The narrative proclaiming a need for immunisation was con-
fronted with anti-narratives that gradually gained momentum,
especially in social media, in the period leading up to November
2009 (NP). Traditional media also received e-mails daily and
reﬂected on them occasionally (NP). These critical voices can be cat-
egorised in several groups. First, a few prominent scientists voiced
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oncerns about the efﬁcacy and safety of the vaccines, e.g. based on
arge-scale meta-studies. They also criticised the close-knit char-
cter of the ‘nerd community consisting of people who  gradually
would] become’ victims of “groupthink” (NP).
Second, some groups had resisted the National Immunisation
rogramme for years, such as religious groups: ‘The objection con-
erns the principle that vaccines pre-empt divine providence’ (NP).
Third, one prominent critical group emphasised the freedom of
hoice of individuals. When a decision was made to start vacci-
ation, all uncertainties were set aside in order to maximise the
accination coverage level. The government ‘always communicates
n an over-simpliﬁed way about the safety and effectiveness of
accines’ (R20). This leaves no room for individual, autonomous
hoice, which ‘does not correspond with uncertainties that prevail
mongst scientists and medical professionals about the vaccines’
R20). This group aimed at ‘well-considered information’ (NP)
bout vaccination.
Fourth, another prominent group centred on an alternative,
olistic approach to healing, i.e. ‘the best vaccine is the one you
ake with your own body’ (R26). Vaccines were regarded as poi-
onous, and as ‘the cause of a range of diseases including autism
nd MS’  (NP). This group was very much concerned about certain
ngredients of the vaccine, including thiomersal and squalene (NP).
Finally, some anti-narratives concerned conspiracy theory per-
pectives: ‘a group of powerful men  want to decimate the world’s
opulation’, ‘the US Army create vaccines as biological weapons
f mass destruction’, etc. (NP). There is ‘no trust in experts [. . .]
hey are merely there to gain money and power [. . .]  You need
o research it for yourself’ (NP). Other anti-authoritarian or ‘con-
erned citizens’ hooked up with dedicated anti-vaccination groups.
hey even went to court to force producers to reveal the vaccine’s
omposition (NP).
These ﬁve types of critical groups were quite successful in
ttracting media attention and inﬂuencing people’s opinions. Most
roups arose ‘quite spontaneously’ and bottom-up; ‘there was no
eal plan’ (R26). The interactions were largely organised through
he Internet on blog websites where people could leave their com-
ents and react to each other. Some notorious Dutch websites
ublished explicit pictures of victims of HPV-vaccination, and the
onitors of these websites posted messages and articles which
ere inspired by information and experiential stories they received
ia e-mails.
Although the ﬁve groups shared their opinions of objecting to
accination and could beneﬁt from joining the bandwagon to ‘artic-
late their longstanding suspicions’ (R20), there was no shared
pirit. For example, people involved with the fourth group ‘found
he conspiracy theories to be too much’ (NP). Therefore, the anti-
arrative was heterogeneous and the ﬁve groups differed in the
xtent to which they disagreed with the niche players. On an epis-
emological level, the critical groups were rather mild in their
riticism of monitoring activities. They acknowledged the existence
f Lareb, emphasised that ‘people should report side effects to this
rganisation’ (R20) and praised its transparency. At the same time,
hey thought that ‘not all reports were registered’ (R26) and that
only the tip of the iceberg was reported’ (R20). They claimed that
lements of safety monitoring were ignored (R20; R26). Moreover,
hey performed post-marketing surveillance themselves: they col-
ected articles and experiences which they mainly received via
-mails, they reacted to publications of post-marketing studies, and
hey studied side effects in order to include them in their communi-
ations. They had their own safety monitoring system (‘I can draw
n a network of experts from all over the world’; NP) that had the
ame approach in mind as professional monitoring (‘In my  latest
ommunication I used 352 scientiﬁc references’; NP).
The lacking sense of urgency that lasted during summer and
arly autumn was reversed in the beginning of November 2009licy 43 (2014) 792–803
when a three-year-old girl died. Suddenly the call for vaccination
became louder; two-thirds of Dutch parents wanted their children
to be vaccinated (NP). This ‘shift in public opinion’ (NP) coincided
with reﬂections in the media on the relationship and commu-
nication between niche advocates and critical groups. The niche
advocates accused the critical groups of causing confusion, being
unapproachable, and being critical just as a knee-jerk reaction to
the government. ‘It is like a belief; they know blindly that they
are right. . . discussions are pointless’ and ‘dangerous’ (NP). Dur-
ing the few face-to-face discussions, the niche advocates aimed at
conviction and perceived that they ‘took the critical voices seri-
ously’ (workshop 2). In parallel, especially for the beneﬁt of the
general public who had difﬁculties making up their minds, niche
advocates, amongst others the minister of health, advertised the
necessity of vaccination, often referring to ‘banishment of other
infectious diseases like polio’ (NP). Moreover, they compared the
risks of adverse effects of the vaccines with risks associated with
‘crossing the street’ (NP). At the same time, niche advocates tried
to marginalise the anti-narratives in their ﬁrm belief that the anti-
narratives ‘could lead to irresponsible actions and even deaths’
(workshop 2). The critical groups complained about the lack of
transparency of governmental agencies and the fact that the niche
players ‘did not take them seriously at all and thought that their
remarks were not sound enough’ (R20; R26). Besides, they regarded
the communication about the vaccination as being organised in a
‘classical and old-fashioned’, top-down and paternalistic way  (R23).
Since the purchase of the vaccines, a large range of organisa-
tions had prepared the vaccination campaign that took form in two
rounds, late November and mid-December 2009. Lareb published
results, based on a survey completed by 2500 people in three days,
revealing that 27% experienced minor inconveniences. The Centre
also received 718 safety reports, mostly about children with fever. A
week later this was  conﬁrmed by international data. After thorough
investigation, Lareb negated the association between the death of
two young children and immunisation.
5.3. Niche phasing out (December 2009–December 2010)
The vaccination period spanned just two months. During this
time the critical groups obtained sufﬁcient media coverage to
attract quite a bit of attention. After this period the general pub-
lic’s interest in the topic and niche activities quickly subsided (NP).
The questions about the need to purchase the vaccines, the commu-
nication plans and functioning of experts led to critical evaluations
by various niche players, such as the ministry of health and the
EMA  (NP). Immediately thereafter, the evaluation of vaccine mon-
itoring once again became relevant because of Q fever outbreaks.
The role of Lareb was  rather favourably reviewed, since the number
and quality of reported adverse events was  regarded as high (Van
Puijenbroek et al., 2010). This made it easier to effectuate the ear-
lier plans for the transfer of vaccine safety monitoring from RIVM
to Lareb. This division of tasks and the increased role for Lareb led
to the solidiﬁcation of the responsibilities of the niche actors.
5.4. In sum
The inﬂuenza case shows how a closed niche around vaccina-
tion monitoring, consisting of organisations that had been used
to follow longstanding rules in contexts of emergency situations
related to infectious diseases, broke away from these rules andtions. Protection processes were needed to sustain this rebuilding,
which was especially critical because of time and anti-vaccination
pressures. Fig. 2 exhibits the dynamics of protection processes,
based on the coding of events.
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. Concluding remarks
This article has focused on the processes and strategies of advo-
ates and opponents in creating, maintaining and/or phasing out
he protective spaces in which the implementation of innovations
hat are perceived as ‘urgently needed’ and ‘risky’ is managed. A
alancing act ensues between fast access and implementation on
he one hand, and a careful monitoring of safety and efﬁcacy on the
ther. The cases presented illustrate novel monitoring practices,
ollowing the accelerated introduction of pharmaceutical products
rganised in protective spaces.
.1. Comparison of cases
The descriptive analysis of the development of the HIV niche,
upported by Fig. 1, shows that active and passive shielding was
 main activity during niche creation, combined with the articula-
ion of expectations, i.e. fear of uncontrolled diffusion, and tentative
etwork building. In the niche maintenance phase, active shiel-
ing and the articulation of expectations were complemented with
urturing activities such as further network building and learning.
hese activities conﬁrmed the major narrative of the niche, thus
egitimising shielding and empowerment processes. These empow-
rment activities were especially aimed at the anti-narratives.
ome groups, such as intravenous drug abusers and haemophil-
ac patients, were excluded and not represented in the niche. They
acked the power to inﬂuence the outside boundaries and the
egitimisation of the niche. Empowerment efforts and protection
trategies, therefore, had the character of simply capturing outside
ctors and dragging them into the niche, only changing the niche’s
arrative on minor points. Other strategies included ignoring anti-
arratives, “overwhelming” anti-actors or threatening to radicalise
r drop out of vital policy processes. Due to these inclusion strate-
ies, the size and scope of the niche broadened in the phasing-outesses over three phases of the inﬂuenza niche development.
period. Nurturing led to solidiﬁcation of the niche activities and
shielding remained in place, even despite diminishing levels of
unmet medical need, which might question the need for protection
(Hommels et al., 2007).
Fig. 2 and the descriptive analysis of the pandemic inﬂuenza
niche show that the institutions involved in vaccination needed to
respond to an emergent pandemic for the ﬁrst time since they had
redrawn their operations during the avian ﬂu a decade earlier. Still,
the reorganisation of the implementation and monitoring struc-
tures had not been completed and would be tested for the ﬁrst time
in a real-life situation. This led the old regime players, and espe-
cially the ministry of health as prime actor, to break open existing
monitoring practices and include new players (Lareb), which called
for experimentation without the opportunity of failure. In other
words, they perceived that a protective space was needed to set up
and test these idiosyncratic practices in a safe and swift way. Niche
advocates, i.e. the ministry of health and several vocal scientists,
introduced resources such as shielding and supported them with
forceful expectations. After the creation of this niche, the expec-
tations and the related niche narrative came under heavy attack
from a heterogeneous set of critical grassroots groups. Their anti-
narratives, i.e. ﬂu is not serious or vaccines are not safe, were picked
up by the press and the public. The two narratives were regarded as
irreconcilable, which led to antagonistic expectations and allowed
no room for including outside actors in the niche network, not
even for strategic or rhetoric reasons. The empowerment activi-
ties were not aimed at capturing critical outsiders or broadening
the niche network. During vaccination a high degree of ﬁrst-order
learning occurred; especially Lareb learnt “on the job” in prepara-
tion for and during the vaccination period. The phasing-out period
of niche development was dominated by evaluating and rethink-
ing niche practices. Some novel practices, such as the role of Lareb,
were solidiﬁed, meaning they were adopted as part of the regular
vaccination regime.
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.2. Conclusions
At this point we are able to answer the ﬁrst part of the research
uestion: How do interactions between protection processes inﬂu-
nce niche development?
First, shielding seems to be a necessary precondition in order for
urturing and empowerment to take place and forms a prominent
ctivity in the niche creation phase. In later phases, shielding legit-
mises nurturing and empowerment activities, while (in return)
hese two processes endorse shielding. Only when nurturing and
mpowerment falter does shielding come under pressure.
Second, the major activity regarding niche protection occurs in
he interaction between nurturing and empowerment. Both pro-
esses work towards the formation of a narrative that legitimises
iche protection. The expectations and learning about innovative
afety monitoring are translated into a narrative that niche advo-
ates use when they interact with actors outside the niche during
heir empowerment work. Both cases show combinations of visions
hat are unchangeable, e.g. fear of stigmatisation in the HIV case and
ear of diffusion in the inﬂuenza case.
Third, empowerment draws close to the network building
spect of nurturing, as actors who share the agenda of technol-
gy development try to enlist or inspire other actors to join the
iche’s network. This network building recruits actors who can
ontribute to the formation and functioning of the development of
n innovation because they provide resources, legitimacy or social
apital in terms of facilitating interactions. Slight changes in the
iche narrative, as the HIV case showed, are taken for granted.
These three insights add to current conceptualisations of niche
rotection, e.g. in Smith and Raven (2012), by showing interactions
etween the niche protection processes and separating the inﬂu-
nce of these processes over three phases of niche development.
his adds a dynamic character to the conceptualisation of niche
rotection in the ﬁeld of pharmaceutical innovations. Moreover,
his article provides useful insights into how to analyse empower-
ent activities in and around niches, especially in the context of
ontested pharmaceutical innovations.
The second part of the research question deals with the link
etween these protection processes and strategy: How do protection
rocesses inﬂuence niche protection strategies?
First, strategies to manage protection concern the relation with
he regime level. In the HIV case it turned out that the niche did not
hange regular safety monitoring and captured a separate position
n the monitoring regime. In that sense, the niche applied neither
o the concept of ‘ﬁt and conform’ nor to ‘stretch and transform’.
he vaccination case showed that the pandemic inﬂuenza period
as a short, experimental excursion from the regular vaccination
onitoring regime, during which new practices were tested and
valuated and then taken up in that regime. Thus the niche practices
onformed more than really transforming the regime. In the context
f niche-regime interactions, the HIV case is particularly interest-
ng because it shows a middle course between conforming to and
ompletely overthrowing existing regime rules. As the HIV exam-
le shows, one can argue that protections can also institutionalise
nd lead to a slightly reconﬁgured regime. This ﬁnding enriches the
pectrum of available niche-regime interactions (Smith, 2007).
Second, the strategies relate to competing and criticising
arratives. The cases show different ways to deal with these anti-
arratives. In the HIV case, niche players attempted to capture
utsiders by minor narrative change or by “overwhelming” them,
gnored anti-narratives and threatened to radicalise or drop out of
ital policy processes. In the pandemic inﬂuenza case, niche players
howed no engagement with anti-narratives.
Although the strategies displayed in the two cases do not neatly
lign to one of the two extreme poles of restrictive versus accom-
odating protection strategies (cf. Table 1), the HIV case leans morelicy 43 (2014) 792–803
towards the latter. The accommodating protection strategy focuses
on reﬂective second-order learning, slower ﬁrst-order learning and
capturing ideas and actors from outside the niche. The pandemic
inﬂuenza case was characterised by niche players maintaining a
low degree of interactions with outsiders, even ignoring them. Their
focus was neither on reconciliation or convergence nor on captur-
ing critical outsiders or broadening the niche network. The case
bends more towards the restrictive protection strategy with robust
expectations, fast ﬁrst-order learning, and no engagement with the
anti-narratives.
This study points at possible advantages and disadvantages of
both strategies. The upside of restrictive strategic niche manage-
ment is the fact that the small core group of included actors can
learn, implement and set up monitoring quickly. Innovations can be
quickly implemented, together with socio-institutional measures
that guarantee safety. The downside is that the excluded actors are
not taken into account or are regarded rather late, leading to sur-
prises, e.g. lower vaccination coverage rates, and in the long run
less robust niche narratives (Rip et al., 1995). Moreover, the liter-
ature on learning also hints at the dangers of seeking premature
consensus and compromises, as this leads to ‘killing’ of fresh ideas
and to tunnel vision (March, 1991).
6.3. Limitations and outlook
The research methodology has some limitations. The major issue
concerns the retrospective nature of at least the HIV case, which
might have led to the re-evaluation of history by interview respon-
dents and workshop participants. We  tried to ameliorate this issue
by providing the timeline of major developments as a backbone
and as a mnemonic device. Furthermore, coding events and espe-
cially dividing the timeline into three phases of niche development
is subject to investigator judgement. We  dealt with this through
independent coding and by comparing codes, which increased the
interrater reliability. There were difﬁculties especially in discerning
the three niche protection processes, e.g. how to discern expecta-
tions from empowerment, which has actually been inherent to the
conceptualisation of protection so far.
The research ﬁndings in this study should be understood within
the context of the cases, which might diminish the external valid-
ity of the ﬁndings. Examples of this contextualisation include
the emancipation of homosexuals (HIV case) and the growing
role of social media and a social movement towards anti-elitist
sentiments (inﬂuenza case). Furthermore, the cases focus on the
Dutch post-marketing monitoring system, which might be atypical
because of the politico-economic tradition and governance culture
of discourse-based decision-making. This led the HIV patient orga-
nisations, for example, to be corporatist/participatory rather than
confrontational/activist. These backgrounds have been taken into
account as much as possible.
In sum, this paper increases our understanding of the manage-
ment of the implementation of innovations in the ﬁeld of drug
development subjected to accelerated approval procedures. This
study characterises different processes that support niche protec-
tion and uncovers patterns between these processes as well as
differences in these processes in the various phases of niche devel-
opment. Accordingly, this study contributes to conceptualising the
dynamics of and strategies for inducing niche protection. As was
mentioned in the introductory section, in the pharmaceutical sector
regulators regard drug safety monitoring tailored to speciﬁc dis-
eases or drugs as a way to organise arrangements for monitoring in
the future. Also technological developments, such as personalised
medicine as a result of pharmacogenomics, might lead to diver-
siﬁcation and segmentation of these socio-institutional practices
for monitoring. This could result in a distributed set of tailor-
made niche protection practices, thus changing the monitoring
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egime. However, the regime could very well remain applicable
o a substantial part of the total pharmaceutical sector, thereby
eaving room for the co-existence of practices and strategies. This
eans that players in the pharmaceutical sector, such as com-
anies and regulators, who have increasingly been organised on
n international level, might need to take idiosyncratic, contextu-
lised practices of post-marketing monitoring into consideration
nd could beneﬁt from doing so.
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